<DOC>
	<DOC>NCT01115712</DOC>
	<brief_summary>The purpose of this study is to evaluate whether 30 mg of pioglitazone administered once daily for up to 28 days to healthy overweight and obese subjects will lead to a significant change in insulin sensitivity, measured in the setting of a hyperinsulinemic euglycemic clamp</brief_summary>
	<brief_title>Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subject has a BMI of greater than 28 kg/m^2 and less than or equal to 38 kg/m^2 Subject has been a nonsmoker and/or has not used nicotine or nicotinecontaining products for at least approximately 6 months Subject is willing to avoid major dietary changes for the duration of the study Subject has history of diabetes (Type 1, Type 2 or steroidinduced) Subject has a history of hypersensitivity to pioglitazone or other thiazolidinediones Subject has a history of liver disease, other than nonalcoholic fatty liver disease or nonalcoholic steatohepatitis Subject has a history of congestive heart failure Subject has a active or past history of atherosclerotic heart disease, heart failure, osteoporosis, osteopenia, recurrent bone fractures, or anemia Subject has a history of stroke, chronic seizures, or major neurological disorder Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological or renal abnormalities or diseases Subject has a history of neoplastic disease within the past 5 years</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>